Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Yaqi WangLifeng YangHua BaoXiaojun FanFan XiaJuefeng WanLijun ShenYun GuanHairong BaoXue WuYang XuYang W ShaoYiqun SunTong TongXinxiang LiYe XuSanjun CaiZeng-Fu ShangZhen ZhangPublished in: PLoS medicine (2021)
The model combining ctDNA and MRI improved the predictive performance compared with the models derived from individual information, and combining ctDNA with HR_feature can stratify patients with a high risk of recurrence. Therefore, ctDNA can supplement MRI to better predict nCRT response, and it could potentially help patient selection for nonoperative management and guide the treatment strategy for those with different recurrence risks.
Keyphrases
- rectal cancer
- locally advanced
- circulating tumor
- neoadjuvant chemotherapy
- phase ii study
- contrast enhanced
- squamous cell carcinoma
- magnetic resonance imaging
- radiation therapy
- free survival
- diffusion weighted imaging
- circulating tumor cells
- machine learning
- cell free
- clinical trial
- lymph node
- deep learning
- health information
- magnetic resonance
- replacement therapy
- combination therapy
- human health
- open label